期刊
CURRENT PHARMACEUTICAL DESIGN
卷 23, 期 38, 页码 5943-5954出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1381612823666171009143840
关键词
PBPK; neonates; pharmacokinetics; retrograde approach; bottom-up approach; pediatric drug research
资金
- Agency for Innovation by Science and Technology in Flanders (IWT) through the SAFE-PEDRUG project [IWT/SBO 130033]
Introduction: The neonatal population remains one of the populations in which appropriate dosing regimens are still lacking, resulting in a large off-label or unlicensed use. Clinical research in these small infants remains a challenge, which sparks the need for modeling and simulation as an additional tool for neonatal drug research. Methods: The use of physiologically based pharmacokinetic modeling in preterm and term neonates is investigated. Results: Throughout the last decade, the use of this modeling technique in this vulnerable population has received increased attention, but still many knowledge gaps exist. Firstly, an overview of the top-down, bottom-up and middle-out approach is given, and then these different modeling tools regarding feasibility and appropriate use are compared. The challenges in applying PBPK to this young population are highlighted and possible solutions are presented. Examples of applications were found in literature and a preference for the combination of a pure bottom-up approach with clinical data (the middle-out approach) was detected. Conclusion: Perspectives to further apply this powerful modeling methodology in this population are described in order to become 'the tool' for the design of First-in-Human and First-in-Neonate trials, and the individualization of dosing in these therapeutic orphans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据